Deltex Med Grp PLC - Issue of Equity
Deltex Medical Group plc
Issue of equity to satisfy outstanding equity-settled non-executive directors' fees
Deltex Medical Group plc (the "Group" or "Deltex Medical") (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today announces the issue of 6,281,822 ordinary shares (the "New Shares") at the price of
Outstanding equity-settled non-executive directors' fees
Further to the announcement issued by the Group on
Details of the New Shares to be issued to each of the Deltex Medical directors are set out in the table below.
|
Director |
Current shares held |
% |
New Shares |
Post transaction holding |
% |
|
|
77,685,286 |
13.46% |
2,167,535 |
79,852,821 |
13.68% |
|
|
15,782,542 |
2.73% |
1,371,429 |
17,153,971 |
2.94% |
|
Mark Wippell |
8,866,446 |
1.54% |
1,371,429 |
10,237,875 |
1.75% |
|
|
2,925,862 |
0.51% |
1,371,429 |
4,297,291 |
0.74% |
Admission
Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. It is expected that admission will take place and dealings in the New Shares will commence on AIM on or around
Total voting rights
Immediately following admission, the Company's issued share capital will be 583,572,367 ordinary shares of
For further information, please contact:
|
Deltex Medical Group plc |
01243 774 837 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Arden Partners plc |
020 7614 5900 |
|
Oscair McGrath
|
|
|
|
|
|
Joint Broker |
|
|
Turner Pope Investments (TPI) Ltd |
0203 657 0050 |
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
a) b) c) Mark Wippell, Non-Executive Director d)
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
See 1 a) above |
|
b)
|
Initial notification /Amendment |
Initial notification |
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Deltex Medical Group plc |
|
b) |
LEI |
213800XN34P6LI8J6M39 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of 1 p each Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583 |
|
b) |
Nature of the transaction |
Settlement of outstanding Non-Executive Director's fees by way of ordinary shares of 1p each in Deltex Medical Group plc |
|
c) |
Price(s) and volume(s) |
a) 2,167,535 b) 1,371,429 c) 1,371,429 d) 1,371,429
|
|
d) |
Aggregated information - Aggregated volume - Price |
6,281,822 shares 1.75p per share |
|
e) |
Date of the transaction |
14 July 2020 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic monitoring space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocols for surgical patients, as well as treating ventilated intensive care patients, including ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from the opportunities associated with: the CV-19 pandemic; the elective surgery backlog; and the higher profile of haemodynamic monitoring which has arisen from the recent consolidation in the sector. The Group aims to provide clinicians with a modern, next generation, single 'haemodynamic workstation' platform which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's clinical condition as well as the skill and expertise of the user. Doing this will enable the Group to partner with healthcare providers to support modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE